SALT LAKE CITY, Nov. 15, 2011 /PRNewswire/ -- Booth - A78/Hall 10 -- Varian Medical Systems, Inc. (NYSE: VAR) will exhibit its PaxScan® digital image detectors and new PaxPower™ X-ray tubes at the MEDICA 2011 International Trade Fair in Dusseldorf, Germany from November 16-19, 2011.
The Varian booth will highlight:
- The PaxPower™ FP 2250SP X-ray tube, a next-generation tube designed for digital radiological imaging systems. The tube uses Varian's a rotating anode technology for high demand applications and can also be used in real-time imaging from fluoroscopy to cardio vascular applications. The X-ray tube is lightweight, small in size and is capable of 1000 watts continuous heat dissipation. "At half the size and twice the power of conventional dual-ended tubes, PaxPower™ tubes have the potential to drive new equipment designs and capabilities much as flat-panel detectors have done for digital imaging over the last five years," said Steve Kimmel, vice president sales and marketing for Varian's X-Ray Products group.
- The PaxScan® 4336R, a 43cm x 36cm detector for digital radiography (DR) that is the first DR panel designed in conformance with National Electronic Manufacturers Association (NEMA) standards to replace film cassettes used in existing radiographic and multi-bucky applications. "A portable 4336R is also available with a hand-held enclosure for use in mobile imaging systems," added Kimmel.
- The PaxScan® 4343R, a 43cm x 43cm detector, which is Varian's largest panel designed for permanent mounting in radiographic tables or wall stands.
European Sales & Service Center
Varian Medical Systems has a dedicated, bonded facility at its service center in Willich, Germany where X-ray tubes are available in inventory for rapid shipment. This facility reloads, rebuilds and distributes medical X-ray tubes for immediate delivery throughout Europe. The center also evaluates and repairs tubes. Varian's X-ray Products Group is headquartered in Salt Lake City, Utah.
"With inventory in our Willich facility and our sales and technical team, we are able to provide quality customer service throughout the European Union," said Stefano Daniotti, European regional manager for Varian X-Ray Products.
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.
FOR INFORMATION CONTACT:
Elaine Rebele, Varian Medical Systems
801-978-5715 or email@example.com
Related medicine technology :1
|SOURCE Varian Medical Systems|
Copyright©2010 PR Newswire.
All rights reserved
. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial2
. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference3
. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint4
. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania5
. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers6
. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)7
. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer8
. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease9
. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies10
. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer11
. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer